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Ataxia with oculomotor apraxia type 1 (AOA1) is an early
onset autosomal recessive spinocerebellar ataxia with a defect in
the protein Aprataxin, implicated in the response of cells to DNA
damage. We describe here the expression of a recombinant form of
Aprataxin and show that it has dual DNA binding and nucleotide
hydrolase activities. This protein binds to double-stranded DNA
with high affinity but is also capable of binding double-stranded
RNA and single-strand DNA, with increased affinity for hairpin
structures. No increased binding was observed with a variety of
DNA structuresmimicking intermediates in DNA repair. TheDNA
binding observed here was not dependent on zinc, and the addition
of exogenous zinc abolished DNA binding. We also demonstrate
that Aprataxin hydrolyzes with similar efficiency the model histi-
dine triad nucleotide-binding protein substrate, AMPNH2, and the
Fragile histidine triadprotein substrate,Ap4A.These activitieswere
significantly reduced in the presence of duplex DNA and to a lesser
extent in the presence of single-strand DNA, and removal of the
N-terminal Forkhead associated domain did not alter activity.
Finally, comparisonof sequence relationships between thehistidine
triad superfamily members shows that Aprataxin forms a distinct
branch in this superfamily. In addition to its capacity for nucleotide
binding and hydrolysis, the observation that it also binds DNA and
RNA adds a new dimension to this superfamily of proteins and pro-
vides further support for a role for Aprataxin in the cellular
response to DNA damage.
Ataxia with oculomotor apraxia type1 (AOA1)2 is an early onset neu-
rodegenerative disorder that is characterized by cerebellar ataxia,
peripheral neuropathy, and hypoalbuminemia (1). Date et al. (2) and
Moreira et al. (3) identified the gene defective in this disorder, APTX,
using linkage analysis. Two different size transcripts were identified for
Aprataxin byNorthern blot analysis and sequencing andwere predicted
to encode short (19 kDa) and long (39 kDa) forms of the protein. A series
of mutations has been described in APTX, primarily localizing to the
histidine triad (HIT) domain centrally located in the molecule (1, 4).
Aprataxin also contains an N-terminal Forkhead-associated (FHA)
domain that binds phosphoproteins and a C-terminal putative zinc fin-
ger DNA binding domain (2, 3, 5, 6). This protein localizes to the
nucleus and nucleolus (6) and has also been shown to interact with
several proteins involved in the cellular response to DNA damage (2,
6–9). These proteins include x-ray cross-complementing protein 1
(XRCC1), XRCC4, poly(ADP-ribose) polymerase 1, and p53 (2, 6–9).
Aprataxin has also been shown to form part of a novel single-strand
break repair complex that includes XRCC1 and DNA ligase 3 (9). This
complex is distinct from the single-strand break repair complex that
includes XRCC1, DNA ligase 3, polynucleotide kinase, and polymerase
. The N-terminal 20 amino acids of the Aprataxin FHA domain was
found to interact with XRCC1 and was dependent on the phosphoryl-
ation of XRCC1 (5, 7). A role for Aprataxin in the cellular response to
DNA damage is further substantiated by enhanced sensitivity of AOA1
cells to a variety of genotoxic agents. AOA1 cells are hypersensitive to
agents that cause single-strand breaks in DNA, including hydrogen per-
oxide and methyl methanesulfonate (6). These cells also display higher
levels of induced chromosomal aberrations in response to these agents
comparedwith control cells. No increased sensitivity was observed after
mitomycin C or ionizing radiation exposure (6, 7). Together these
observations point to a role for Aprataxin in the cellular response to
DNA single-strand breaks. Evidence for such a role was recently pro-
vided by Mosesso et al. (10), who demonstrated an inability of AOA1
cells to process camptothecin-induced DNA damage using the comet
assay.
It remains unclear as to what the exact role of Aprataxin is in the
cellular response to DNA damage. The examination of the putative
functional domains within Aprataxin provides evidence as to what this
rolemight be. The presence of aHIT domain in the central region of the
molecule suggests that it has nucleotide hydrolase activity. The HIT
domain superfamily of proteins is characterized by the presence of the
HIT motif, HXHXHXX where X is a hydrophobic amino acid. This
superfamily consists of four branches including histidine triad nucleo-
tide-binding protein (HINT), fragile histidine triad (FHIT), galactose-1-
phosphate uridylyltransferase, and DcpS, a scavenger pyrophosphatase
(11, 12).
Phylogenetic tree analysis by Date et al. (2) and Hirano et al. (13)
showed that Aprataxin branches more closely with FHIT family pro-
teins. The FHIT family has been shown to hydrolyze diadenosine
polyphosphate substrates. Contrary to this, Aprataxin has also been
classified as a HINT protein (11, 14) based on its 31% identity with the
rabbit and human HINT sequences over an 86-amino acid region (11).
The recent reports on the catalytic activity of bacterially expressed
recombinant Aprataxin have also been conflicting (13, 15). Hirano et al.
(13) reported that due to intramolecular inhibition by the FHA domain,
there was no significant hydrolysis on GpppBODIPY, a known fluoro-
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genic substrate for FHIT family proteins (16). When they added the
N-terminal FHA domain separately from the C-terminal portion of the
Aprataxin protein, they found low levels of activity, Kcat  1.78 
103s1, and mutations in the HIT domain abrogated this activity. In
contrast, Seidle et al. (15) obtained similar low levels of activity (Kcat
0.4 103s1) using the full-length protein on the same substrate but
observed no apparent inhibition by the FHA domain. They also dem-
onstrated activity (Kcat 2.8 103s1) on the HINTmodel substrate,
tert-butoxycarbonyl-L-lysinemethylcoumarinamide, anAMPmolecule
linked to lysine.
Here we describe the expression of a yeast recombinant human
Aprataxin protein and its purification to a single detectable band after
SDS-PAGE.We demonstrate for the first time that Aprataxin possesses
both DNA and RNA binding activities as well as a capacity to hydro-
lyze nucleotide-based substrates. The presence of DNA significantly
reduced nucleotide hydrolase activity.
MATERIALS ANDMETHODS
Expression Construct—Aprataxin was cloned into the yeast overex-
pression plasmid pMH1, which has been adapted for the use of the
self-cleaving affinity technology of New England Biolabs IMPACT-CN
system (17). The entire coding region of human APTX (NP_778243)
lacking the stop codon was amplified using primers 5-TTTGTCGA-
CATGATGCGGGTGTGCTGGTTG-3 and 5-CTGTGTCCAGT-
GCTTCCTGAGATG-3, designed to introduce a SalI site at the 5 end
of the PCR product. This was digested with SalI and cloned into pMH1,
which had been digested with SalI-SmaI to remove the MLH1 gene,
creating pMHA. This cloning strategy results is the addition of a glycine to
the C terminus of the human Aprataxin protein after intein cleavage. The
Aprataxin V263Gmutant was cloned as above and had been previously
generated, as described in Gueven et al. (6). Bacterial expression con-
structs of full-length, N-terminal deleted, C-terminal deleted, and
N-and C-terminal deleted forms of Aprataxin were prepared using PCR
with the following primer sets: 5-CGGGATCCATGATGCGGGTGT-
GCTGGTTG-3 and 5-CCGCTCGAGTCACTGTGTCCAGTGCT-
TCCT-3; 5-CGGGATCCTCAGGCAACAGTGATTCTATAGA-3
and 5-CCGCTCGAGTCACTGTGTCCAGTGCTTCCT-3; 5-CGG-
GATCCA TGATGATGCGGGTGTGCTGGTTGG-3 and 5-CCG-
CTCGAGTCAACGAAGGGGCAGCTTCA-3; 5-CGGGATCCT-
CAGGCAACAGTGATTCTATAGA-3 and 5-CCGCTCGAGTCA-
ACGAAGGGGCAGCTTCA-3, respectively. These amplifications intro-
duced BamHI and XhoI sites for cloning into pGEX-6P-1 (Amersham
Biosciences). This cloning strategy leads to the addition of five amino acids
(GPLGS) to the N terminus after cleavage with PreScission protease.
Overexpression and Purification—The pMHA construct was intro-
duced into Saccharomyces cerevisiae strain, BJ2168, using the standard
lithium acetate transformationmethod followed by selection on trypto-
phan drop out minimal media. Subsequent growth and overexpression
was also performed in this medium at 25–30 °C. Transformants were
used to inoculate overnight starter cultures with 2% glucose as the car-
bon source. These saturated cultures were diluted 1/100 and regrown in
media using 2% glycerol and 2% lactate as carbon sources to an A600 of
0.9. Cells were harvested andwashed once in phosphate-buffered saline,
then cell pellets were resuspended in an equal volume of chitin 500
buffer (20 mM Tris, pH 8, 1 mM EDTA, 1 mM PMSF, 10% glycerol, 500
mM NaCl) before freezing small beads on dry ice. Frozen cells were
ground in dry ice using a coffee grinder. Ground cells were defrosted on
ice and resuspended in 5 volumes of chitin 500 buffer with 0.01 mM
Tris(2-carboxyethyl)phosphine. This lysate was centrifuged at 20,000
g for 30 min at 4 °C. All the subsequent purification steps were per-
formed at 4 °C. The clarified lysate was loaded at 0.5ml/min onto a 1-ml
chitin column equilibrated with chitin 500 buffer. The column was
washed with 10 volumes of chitin 500 buffer, 5 volumes of chitin 1000
buffer (20 mM Tris, pH 8, 1 mM EDTA, 1 mM PMSF, 10% glycerol, 1000
mM NaCl), 5 volumes of cleavage buffer (20 mM Tris, pH 8, 500 mM
NaCl, 10% glycerol, 1 mM EDTA pH8, 50 mM dithiothreitol, 1 mM
PMSF) without dithiothreitol, then with 5 volumes of cleavage buffer
with dithiothreitol and clamped to enable cleavage (16 h at 4 °C).
Cleaved protein was eluted, concentrated, and diluted to a final concen-
tration of 200 mM NaCl with water then loaded at 0.3 ml/min onto a
1-ml Biorex 70 cation exchange resin (Bio-Rad) equilibrated with buffer
A200 (10 mM Tris, pH 7.5, 0.5 mM, EDTA, 1 mM PMSF, 10% glycerol,
200mMNaCl). The columnwaswashedwith 20 volumes of buffer A200
before elution with 10 volumes of buffer A380 (10 mM Tris, pH 7.5, 0.5
mM, EDTA, 1 mM PMSF, 10% glycerol, 380 mM NaCl), collecting 1-ml
fractions. Peak fractions were pooled and concentrated then diluted
with an equal volume of water before snap-freezing on dry ice and
subsequent storage at 70 °C. Purity was assessed by 15% SDS-poly-
acrylamide gel electrophoresis and subsequent Coomassie R250 stain-
ing as well as Western blot analysis using a rabbit anti-Aprataxin anti-
body raised against the full-length yeast recombinant protein. For
experiments comparing the effect of EDTAon the recombinant protein,
2 protein preparations were made in parallel as above either with 1 mM
EDTA in all buffers or was left out for control no EDTA preparation.
The mutant V263G protein was purified as outlined above for the
chitin affinity chromatography strategy, with the inclusion of an ATP
wash (5 volumes, 20 mM Tris, pH 8, 200 mM KCl, 10% glycerol, 3 mM
MgCl2, and 200 MATP) incorporated after the chitin 1000 wash. This
was included to remove a 70-kDa co-purifying protein that appears to
be a chaperone protein (HSP70) based on previous reports (17). Also,
cleavage was performed at a higher temperature, 16 °C and for longer
(24 h), to enhance the poor cleavage. In experiments where the V263G
protein was used, wild type protein purified in the same manner was
employed. The bacterial pGEX-6P-1 constructs were transformed into
BL21 E. coli for overexpression at 25 °C. Isopropyl 1-thio--D-galacto-
pyranoside (0.1 mM) was added for 2.5 h to induce protein expression.
Cells were lysed by sonication and clarified by centrifugation (20,000
g  40 min). The supernatant was incubated with glutathione-Sepha-
rose resin (Amersham Biosciences), glutathione S-transferase fusion
protein was cleaved with an overnight incubation with PreScission pro-
tease, and proteins were recovered in the eluate. These proteins were
further purified on a Biorex 70 cation exchange resin.
DNA Binding Assays—DNA binding was investigated using electro-
phoretic mobility shift assay using different size single-strand and
duplex oligonucleotides. Oligonucleotides were radiolabeled by
polynucleotide kinase (Invitrogen) and annealed to create duplexes.
Sequences are based on those used by Chi and Kolodner (18), which
are designed to minimize secondary structure. A common 21-base
bottom oligo, 5-TCAGCAGATAGGAACCATACT-3, was annealed
to the top sequences to create the various DNA structures: homoduplex,
5-AGTATGGTTCCTATCTGCTGA-3; mismatch, (G-A), 5-AGTAT-
GGTTCCGATCTGCTGA-3; flap, 5-AGTATGGTTCCTTAGACG-
ACT-3; 6-base pair hairpin, 5-AGTATGGTTCGAGTACGTAC-
TCCTATCTGCTGA-3; nick, 5-ATCTGCTGA-3 and 5-AGTAT-
GGTTCCT-3; one-base gap, 5-ATCTGCTGA-3 and 5-AGTATG-
GTTCC-3. RNAbindingwas investigatedusing a21-basepair dicedRNA
sequence (DNA-PKcs) kindly provided by Dr. Rick Woods. The 11- and
37-bp duplexes were created as outlined above by annealing sequences:
5-AGTATGGTTCC-3 and 5-GGAACCATACT-3; 5-ATGTGAAT-
CAGTATGGTTCCTATCTGCTGAAGGAAAT-3 and 5-ATTTCCT-
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TCAGCAGATAGGAACCATACTGATTCACAT-3. A nick was intro-
duced into the 37-bp sequence after nucleotide 16 by annealing the two
corresponding oligonucleotides. Base 17was left out, and the same strategy
was used to create a gapped substrate.
Binding reactions were performed on ice for 15min in 10mMHEPES,
pH 7, 20 ng/l acetylated bovine serum albumin, 100 mM NaCl (unless
otherwise stated), and 8% sucrose. The nucleic acid substrates were
present at 1 pmol per reaction unless otherwise stated, and Aprataxin
was included as indicated. Zinc sulfate was included where indicated by
preincubating Aprataxin with zinc for 15 min before the addition of
radiolabeled DNA duplex. Samples were run in 6% non-denaturing
polyacrylamide gels containing 0.5Tris borate-EDTAbuffer at 20mA
for 25–35 min at 5 °C. Gels were dried on Whatman No. 3MM and
visualized by x-ray film. Quantitation was performed by scanning films
and using ImageQuant software (Amersham Biosciences). The percent
bound was estimated as bound/(bound unbound).
Catalytic Activity Assays—Initial experiments using pH 6, 7, and 8
HEPES buffer established that maximum catalytic activity was obtained
at pH 7, which was used for subsequent investigations. Reactions were
performed at 30 °C for 20 min to 3 h in 10 mM HEPES, pH 7, 30 mM
NaCl, 1 M Aprataxin with nucleotide substrates, ATP (Sigma), dATP
(Fisher), AMPNH2 (Sigma), and Ap4A (Sigma) at 0.02–1.5 mM in 10-l
reactions. DNA duplex or single-strand oligonucleotide was added as
indicated.
The products of hydrolysis were resolved and quantitated using anion
exchange high performance liquid chromatography on a Hypersil SAX
column 250 4.6 mm (Phenomenex). Parent substrates used here and
products of the hydrolysis reactions, AMP and ATP, were identified by
retention times and co-elution with standards and quantified based on
their absorbance at 259 nm. The reaction products were resolved using
a gradient starting with 1 mM ammonium phosphate buffer, pH 2.8,
0–40%, run against 750 mM ammonium phosphate buffer, pH 3.7, for
all reactions except AMPNH2. These reaction products were resolved
using a gradient starting with water 0–40% run against 750 mM ammo-
nium phosphate buffer, pH 3.7, where AMP was the only detectable
product. Peak areas were used to generate a standard curve for AMP
over the range 50–1000 pmol (R2 0.99), indicating both a linear and
sensitive detection of the primary product of hydrolysis. Determina-
tions of kinetic parameters weremade by estimating the best fit curve to
theMichaelis equation using an Excel macro available online at Univer-
sity of Paisley, Department of Biological Sciences.
Phylogenetic Tree Analysis—Human sequences (NP_778243, NP_005331,
Q9BX68, NP_612638, AAL40394, NP_000146, NP_054745, AAH32336,
including Hint2 and Hint3) were used from each branch Hint1, FHIT,
galactose-1-phosphate uridylyltransferase, DcpS, andAprataxin to identify
orthologs in mouse (NP_079821, NP_032274, NP_057867, NP_081306,
AAC24117) bony fish (NP_999894, AAH81526, CAF92838, AAP47149,
NP_957034) and yeast (NP_014901,NP_010158,NP_009574,NP_014816,
NP_010591) bypBAST.Thesewere then alignedbyon-lineClustalWmul-
tiple sequence alignment program using the default parameters at the
European Bioinformatics Institute web site. The alignment was imported
intoMolecularEvolutionaryGeneticAnalysis (MEGAVersion2.1) tobuild
a Neighbor-Joining tree with pairwise deletion and Poisson correction
using human Chk2 (NP_001005735) as the root. The reliability of the
inferred tree was analyzed by the bootstrap test, 1000 replications.
RESULTS
Cloning and Expression of Recombinant Aprataxin—Full-length
Aprataxin cDNAwas cloned into a self-cleaving affinity expression con-
struct as described by Hall and Kunkel (17). This yeast expression sys-
tem is driven by a GAL1 promoter inducing overexpression of an
Aprataxin fusionprotein.Purificationof the fusionproteinwasachievedby
affinity chromatography utilizing the chitin binding domain followed by
dithiothreitol-induced self-cleavage. Further purification was carried out
using cation exchange chromatography. This approach generated a single
detectable protein byCoomassie R250 staining (Fig. 1A). An antibody gen-
erated against the full-length Aprataxin protein did not detect any degra-
dation products byWestern blot analysis (Fig. 1B).
This expression system was also used to produce the V263G mutant
form of Aprataxin (Fig. 1C). This mutation is located within the HIT
motif of Aprataxin and was identified in a Japanese AOA1 patient (2).
The recovery ofmutant proteinwas 95-fold lower than that obtained for
the wild type protein after elution from the chitin resin and less pure
as is evident from Fig. 1C. This was not due to reduced levels of the
induced fusion protein in yeast cell extracts, which were comparable
by Western blot analysis (data not shown), but due to reduced bind-
ing to the chitin resin and extremely inefficient cleavage even with
increased temperature and length of the cleavage compared with the
wild type protein.
DNABinding Activity—AOA1 cells are hypersensitive to DNA-dam-
aging agents and are defective in repair of DNA single-strand breaks (6,
10). Aprataxin has also been shown to bind to several proteins involved
inDNA repair and localizes to the site of DNAdamage. Accordingly, we
investigatedwhetherAprataxinwas capable of binding directly toDNA.
Using gel electrophoretic mobility shift assays, we demonstrated that
recombinant Aprataxin was able to bind to a 21-base pair double-
stranded DNAmolecule (Fig. 2A, lanes 5 and 6). A single discrete bind-
ing species was observed at low concentrations of Aprataxin. Increasing
FIGURE 1. A, Coomassie R250-stained 15% SDS-polyacrylamide gel with 1.5 pmol (lane 1) and 4.5 pmol (lane 2) of purified Aprataxin (40 kDa). A histogram of the central region of the
4.5-pmol lanewas generated by the ImageQuant program (AmershamBiosciences) andwas aligned to the left of the image. B, Western blot of purified Aprataxinwith 1.5 pmol (lane
1) and 4.5 pmol (lane 2) probed with a rabbit anti full-length Aprataxin antibody. A histogram of the central region of the 4.5-pmol lane was generated by ImageQuant program
(Amersham Biosciences) and was aligned to the left of the image. C, Western blot of purified wild type Aprataxin (lane 1) and V263G (lane 2) probed with a rabbit anti-full-length
Aprataxin antibody, Showing a less pure preparation.
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the concentration of Aprataxin gave rise to a second andmore retarded
band, indicating more than one molecule of Aprataxin binding to each
duplex (Fig. 2A, lane 6). Under the conditions used Aprataxin failed to
form a stable complex with single-stranded DNA, but there was evi-
dence of some nonspecific binding or unstable complex formation at
higher Aprataxin concentrations (Fig. 2A, lane 4).
One of the domains identified in Aprataxin by sequence homology
was a C2H2-type zinc finger (2, 3). The formation of the zinc finger struc-
ture depends on a zinc ion that is coordinated by the two cysteines and two
histidines, enabling binding toDNAorRNA. Because Aprataxin contains
a putative zinc finger domain, protein was purified in the presence and
absence of EDTA. This chelator failed to alter the binding to either
single or double-strand DNA (Fig. 2A, lanes 3–6 (EDTA), lanes 7–10
(EDTA)). Unexpectedly, the addition of zinc under both conditions
abolished DNA binding (Fig. 2A, lanes 11–14). The other domain that
could be responsible for this DNA binding activity is the HIT domain,
which is known to bind and hydrolyze nucleotide-based substrates. To
investigate the possible role of this domain we generated a mutation in
the HIT motif that removes one of the key hydrophobic amino acids in
the consensus sequence, V263G. When used in the electrophoretic
mobility shift assays in parallel with wild type protein under the same
conditions the V263Gmutant form failed to bind duplexDNA (Fig. 2B).
To determine the affinity of Aprataxin for duplex DNA, binding was
performed with increasing Aprataxin concentration. When 50% of
duplex DNA is bound by Aprataxin, a Kd value of 0.38 Mwas obtained
(Fig. 2C). To further investigate binding to single-stranded DNA, form-
aldehyde cross-linking was employed. Under these conditions a distinct
binding species was observed (Fig. 2D, lane 4). As the concentration of
formaldehyde was increased, the amount of this stabilized complex
increased (lane 6). It is also evident that some cross-linked material
remained in the well.
To investigate the kinetics of binding, a time course experiment was
performed. Because this was found to be rapid, incubations were per-
formed on ice. Within 1 min post-incubation, Aprataxin DNA binding
was evident (Fig. 3A). Competition experiments with unlabeled duplex
DNA were used to investigate the dynamics of binding to DNA and
whether single-stranded DNA could disrupt the Aprataxin-DNA com-
plex. The results in Fig. 3B reveal a linear decrease of 57% (S.D. 9) with
each fold increase in unlabeled competitor over the range 1–8-fold. To
investigate the dynamics of the competition with either duplex or sin-
gle-stranded DNA, unlabeled competitor DNA was added at 8-fold
excess for 1–20min. The duplexDNA at 1min (Fig. 3C, lane 3) was able
to quickly compete for Aprataxin to the same level as that observed at
the 20min time point (lane 5).When an 8-fold excess of single-stranded
DNAwas added to the Aprataxin-DNA complex, it failed to disrupt the
complex at 1, 10, and 20min (Fig. 3C, lanes 6–8), which is in agreement
with the reduced affinity of Aprataxin for single-strand DNA. To inves-
tigate the footprint size of Aprataxin on duplex DNA, we employed 11-,
21-, and 37-bp substrates. The results for Fig. 3D show that the affinity
of Aprataxin for the 11-bp fragment is significantly less than that for the
other 2, and only a single retarded fragment was observed. Two distinct
binding species were observed with the 21-bp substrate and up to 4
binding species with the 37-bp fragment, suggesting a footprint size of
10 bp. In view of the increased affinity of Aprataxin for the 37-bp
FIGURE 2. A, binding of Aprataxin (APTX) to a 21bp DNA duplex (DS) and single-stranded oligo (SS) as detected by electrophoretic mobility shift assays. Lanes 1 and 2 are control
reactions lacking Aprataxin; lanes 3–6 show Aprataxin purified in the presence of EDTA (APTXE) binding to SS and DS DNA (1 pmol) with increasing protein; lanes 7–10 show
Aprataxin purified in the absence of EDTA (APTX-E) binding to SS andDSDNA (1 pmol) with increasing protein; lanes 11–14 show the effect of zinc sulfate (200M) on Aprataxin DNA
binding. A single asterisk indicates unboundDNA, two asterisks indicate theAprataxin-DNA complex, and three asterisks indicatemore than onemolecule of Aprataxin binding to one
DNAmolecule.B, the affinity ofwild type andmutant (V263G)Aprataxin for duplexDNA. TheAprataxin concentration required tobind50%of theduplexwas estimated from theplot
of duplicate reactionswith increasingprotein concentration.C, the roleof theHITdomain inDNAbindingactivity. Thewild type control (lanes 2and3) or theHITmotifmutantprotein,
V263G (lanes 4 and 5) were incubated with 1.5 pmol of homoduplex DNA. A single star indicates unbound DNA, and two asterisks indicates the Aprataxin-DNA complex. D,
formaldehyde (FORM.) cross-linkingofAprataxin to single-strandDNA. Lanes 1 and 2 show theunstablebindingofAprataxin to single-strandedDNA (2pmol)with increasingprotein.
Lanes 3–6 are the same conditions with the addition of formaldehyde. Lanes 3 and 4, 0.74% formaldehyde; lanes 5 and 6, 1.6% formaldehyde. Lanes 7 and 8 are control reactions to
ensure that the cross-linked species observed are specific to the addition of Aprataxin. Binding reactions were performed as described under “Materials and Methods” but after
binding the samples were incubated at room temperature for 5min (for cross-linking) then returned to ice just before loading. A single asterisk indicates unboundDNA, two asterisks
indicate the Aprataxin-DNA complex, and three asterisks indicate aggregates of cross-linked Aprataxin-DNA complex in the well.
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duplex fragment, we investigated the capacity of Aprataxin to bind to
a larger single-strand oligonucleotide (37 nucleotides). In contrast to
that observed with the 21-mer single-strand oligonucleotide, a stable
Aprataxin-DNA complex was observed with the longer oligonucleo-
tide in the absence of a cross-linking agent (Fig. 3E). No additional
shifted binding species here observed with increasing Aprataxin
concentration, indicating that no additional molecules of Aprataxin
bound the oligonucleotide.
Aprataxin has been shown to interact with XRCC1 and poly(ADP-
ribose) polymerase, both of which are involved in base excision repair
and repair of single-strand breaks. To investigate whether Aprataxin
displayedDNA structure specific binding, we employed a series of DNA
structures that mimic various transition states in the process of repair.
The introduction of a single mismatch (G-A) into the duplex sequence
had no effect on efficiency of binding compared with the homoduplex
(Fig. 4A). The efficiency of binding was reduced to between 28 and 72%
when either a single flap, nick, or gap was introduced into the duplex.
However, all of these structures effectively give rise to a shorter contin-
uous duplex for whichAprataxin has a significantly reduced affinity (see
Fig. 3D). The introduction of a nick or a gap into the larger 37-bp duplex
did not lead to a significant increase in DNA binding affinity compared
with the homoduplex (Fig. 4B).
Gueven et al. (6) have shown that Aprataxin is localized not only to
the nucleus but also the nucleolus, where it associates with nucleolin.
This nucleolar localization could mean it associates with RNA, as has
been reported for nucleolin (19, 20). Because Aprataxin binds efficiently
to duplex DNA, we investigated whether it could also bind double-
stranded RNA. The results in Fig. 5A show that Aprataxin displays a
FIGURE 3.DNAbinding characteristics of Aprataxin. A, time course for stable Aprataxin-DNA complex formation. Aprataxin (3pmol) was incubatedwith 1 pmol of DS DNA duplex
for 1–30 min before electrophoresis. A single asterisk indicates unbound DNA, and two asterisks indicate the Aprataxin-DNA complex. B, stability of the Aprataxin-DNA complex.
Preformed Aprataxin-DNA complex was used in competition experiments with increasing amounts of unlabeled DNA (COMP.). Aprataxin (3pmol) was incubated with 1 pmol of DS
DNA duplex for 15 min before the addition of 0–8 pmol of unlabeled competitor duplex 5 min before electrophoresis. A single asterisk indicates unbound DNA, and two asterisks
indicate theAprataxin-DNAcomplex.C, stability of theAprataxin-DNAcomplex in thepresenceof an8-foldexcess coldDSDNAorSSDNAover time.Aprataxin (3pmol)was incubated
with 1 pmol of DS DNA duplex for 15min (lane 2). An 8-fold excess (8pmol) of unlabeled DS duplex was added to this preformed Aprataxin-DNA complex for 1, 10, and 20min (lane
3–5) or unlabeled SS DNA for 1, 10, and 20min (lanes 6-8). A single asterisk indicates unboundDNA, and two asterisks indicate the Aprataxin-DNA complex.D, binding of Aprataxin to
an 11-bp (lanes 1–5), 21-bp (lanes 6–10), and 37-bp (lanes 11–15) duplex with increasing protein concentration (3–15 pmol) to estimate the binding footprint on DNA (1 pmol). The
arrowheads indicateeachof thediscrete speciesdetected. Binding to the11-bpduplexgave rise toonediscretebandat thehighestprotein concentration (lanes 4and5). Twodiscrete
bands were observed on the 21-bp duplex (lanes 9 and 10) and 4 on the 37-bp duplex (lane 15). The very lower band across all lanes is the un-incorporated nucleotide after
radiolabeling. This happens to co-migrate with the unbound 11-bp duplex. E, binding of Aprataxin to a 37-mer single-strand oligonucleotide (2 pmol). Binding was carried out with
an increasing amount of Aprataxin (lanes 2 and 3). The percent found was estimated using ImageQuant program.
FIGURE4.Comparisonof Aprataxin binding to variousDNA structuresmimicking
possible transition states during repair. A, structures investigated include a single
flap, mismatch (G-A), nick, and gap as compared with the homoduplex (HOM) DNA
substrate. Aprataxin (2 pmol) was incubated with 1 pmol of each radiolabeled 21-bp
DNA substrate for 15 min before electrophoresis. A single asterisk indicates unbound
DNA, and two asterisks indicate Aprataxin DNA complexes. B, comparison of
Aprataxin (3 and 6 pmol) binding to a 37-bp homoduplex and nicked-homoduplex
and single nucleotide gap homoduplex (2 pmol of each). Incubation was for 15 min.
The percent bound as compared with the homoduplex control was estimated using
the ImageQuant program (Amersham Biosciences) and is indicated in parentheses. A
single asterisk indicates unbound DNA, and two asterisks indicate the Aprataxin-DNA
complex.
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similar affinity for binding double-stranded RNA and DNA. Because it
is not expected that RNA in the nucleolus will be double-stranded but
capable of giving rise to secondary structures composed of double-
stranded regions, such as hairpin loops, the binding we observe here
may be explained by Aprataxin binding to RNA hairpin loops. This is
supported by the results in Fig. 5B which show that Aprataxin binds to
a duplex structure designed to create a centrally located 6-base pair
hairpin loop. This binding occurs with greater affinity than with the
homoduplex DNA.
Catalytic Activity of Aprataxin—AHITdomain has been shown to be
centrally located in Aprataxin (3, 6). This domain characterizes a super-
family of proteins with nucleotide hydrolase and transferase activity
(11). Aprataxin has been classified as a HINT protein within the HIT
superfamily on the basis of sequence analyses (11, 14). We investigated
whether Aprataxin has activity characteristic of a HIT or HINT protein
using a high performance liquid chromatography-based assay to assess
nucleotide cleavage.WhenAMPNH2 (amodel substrate for HINT pro-
teins) was employed as a substrate for Aprataxin, the cleavage product
generated, AMP, was identified by retention time and co-elution with
an AMP standard. The catalytic activity of Aprataxin on AMPNH2 sub-
strate was 10.06 103s1 (Fig. 6A). This activity was comparable with
that obtained with the FHIT substrate Ap4A with an activity of 10.79
103s1, producing AMP and ATP as the products of hydrolysis (Fig.
6A). Very low activity was obtained when ATP (0.26  103s1) was
used as the substrate, and there was no detectable hydrolysis of dATP
over a time period of 3 h. To further investigate the catalytic activity of
Aprataxin on Ap4A (Fig. 6B) and AMPNH2 (Fig. 6C) substrates, we
estimated several kinetic parameters. The turnover values were compa-
rable and low for both Ap4A (Kcat  11.5  103s1) and AMPNH2
(Kcat  19.5  103s1). The affinity of Aprataxin for these two sub-
strateswas vastly different, with a 46-fold higher affinity forAp4A (Km
18.0 M) than AMPNH2 (Km  837.5 M). The V263G mutant dis-
played no detectable activity on the Ap4A substrate.
To determine whether the DNA binding by Aprataxin might influ-
ence hydrolytic activity, we monitored the catalytic activity in the pres-
ence of DNA. The addition of increasing concentrations of duplexDNA
to a reaction mix containing the Ap4A substrate significantly reduced
catalytic activity. At 50% inhibition the Ki for duplex DNA was 0.05 M
(Fig. 7A). Single-stranded DNA was less effective, with a Ki of 3.8 M at
50% inhibition (Fig. 7B). The kinetics of inhibition reflected the binding
capacity of the different forms of DNA observed in the electrophoretic
mobility shift assays. This inhibitionmight be explained by competition
between the Ap4A and DNA for the catalytic site. Alternatively, DNA
might induce a conformational change in Aprataxin after binding,
which would alter access by Ap4A to the active site.
A previous report has shown that the enzymatic activity of Aprataxin
is negatively regulated by an intramolecular interaction involving the
N-terminal domain (13). They showed that an N-terminal truncated
form of the protein was substantially more active than the purified full-
length form. This N-terminal region corresponds to the FHA domain
which binds to a phosphorylated region of XRCC1 (7, 9). We investi-
gated the role of the FHA and other functional domains on the nucleo-
tide hydrolase and DNA binding activities of Aprataxin using a series of
truncated recombinant forms (Fig. 8A). The purified proteins employed
are shown in Fig. 8B. Use of the Ap4A substrate demonstrated that
full-length Aprataxin and an N-terminal-truncated form lacking the
FHA domain had comparable hydrolytic activities with Kcat values of
17.1  103 and 17.6  103s1, respectively (Fig. 8, C and D). The
other truncated forms of Aprataxin had no detectable hydrolase activity
(Fig. 8A). Furthermore, only the full-length and N-terminal-truncated
forms of Aprataxin formed stable complexes withDNA (Fig. 8, E and F).
In addition, the use of the XRCC1 triply-phosphorylated peptide that
was previously shown to bind the FHA domain of Aprataxin (9) did not
FIGURE 5. A, comparison of Aprataxin binding to
DNA and RNA. Aprataxin was incubated with 0.4
pmol of radiolabeled DS DNA or RNA for 15 min
with 0 pmol (lanes 1 and 4), 1 pmol (lanes 2 and 5),
and 2 pmol (lanes 3 and 6) of Aprataxin. A single
asterisk indicates unbound DNA or RNA, and two
asterisks indicates the Aprataxin-DNA complex. B,
comparative binding of Aprataxin to homoduplex
(21 bp) hairpin duplex. To investigate differences
in affinity to this secondary structure as compared
with homoduplex DNA, Aprataxin (0, 1.5, 3, and 6
pmol)wasbound to2pmolof radiolabeledhomo-
duplex (lanes 1–4) and hairpin duplex (lanes 5–8)
for 15 min. A single asterisk indicates unbound
DNA, and two asterisks indicate the Aprataxin-
DNA complex.
FIGURE 6. A, catalytic activity of Aprataxin on a range of nucleotide-based substrates.
Aprataxin was incubated for 3 h with 1.5 mM concentrations of each putative substrate
(Ap4A, AMPNH2, dATP, and ATP) at 30 °C. The amount of AMP produced over this time
wasused to calculate the reactionvelocity.B, kinetic parameters ofAprataxinon theFHIT
substrate, Ap4A. A plot of the activity obtained in the presence of a range of Ap4A sub-
strate concentrations (0.02–1.5 mM) versus velocity (pmol of AMP produced/s). These
data, performed in duplicate, were fitted to the Michaelis equation to calculate the Km
and Kcat (given under the curve). C, kinetic parameters of Aprataxin on the HINT sub-
strate, AMPNH2. A plot of the activity obtained in the presence of a range of AMPNH2
substrate concentrations (0.1–1.5 mM) versus velocity (pmol of AMP produced/s). These
dataperformed induplicatewere fitted to theMichaelis equation to calculate theKm and
Kcat (given under the curve).
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interfere with either the DNA binding or nucleotide hydrolase activities
(results not shown). A summary of the results for catalytic and DNA
binding activities for the different forms appears in Fig. 8A.
Sequence Analysis of the HIT Superfamily—There exists some dis-
agreement on the relationship of Aprataxin to the other HIT superfam-
ily members as to whether it is more closely related to the FHIT or
HINT branches (2, 11, 13, 14). To address this we have performed a
phylogenetic analysis with members from all branches and several
orthologs from each to gain amore robust insight. Sequences from each
branch for human, mouse, bony fish, and yeast were aligned by Clus-
talW and used to build a Neighbor Joining bootstrap consensus tree.
When this analysis was applied, Aprataxin formed a discrete cluster like
each of the other previously described branches of the HIT superfamily,
HINT, FHIT, galactose-1-phosphate uridylyltransferase, andDcpS (Fig.
9). Each branch is deeply rooted with a yeast ortholog.
DISCUSSION
It is well established that Aprataxin plays a role in protecting cells
against genotoxic stress. This evidence stems from its interaction with a
number of proteins involved in DNA break repair, including poly(ADP-
FIGURE7.A, the effect of the 21-bpduplexDNAon
the catalytic activity of Aprataxin (1 mM) using
Ap4A as a substrate. The velocity of the reaction is
expressed as a percent of the control reaction,
that has no DNA and is plotted against increasing
DNA concentration in the presence of 500 M
Ap4A. The concentration at which 50% inhibition
occurs is 0.05 M DNA. B, the effect of the 21-bp
single-stranded DNA on the catalytic activity of
Aprataxin (1 M) using Ap4A as a substrate. The
velocityof the reaction is expressedas apercentof
the control reaction, which has no DNA and is
plotted against increasing DNA concentration in
the presence of 500 M Ap4A. The concentration
at which 50% inhibition occurs is 3.8 M DNA.
FIGURE 8. Structure and activity of different recombinant forms of Aprataxin. A, schematic representation of full-length Aprataxin and truncated forms and a summary of
catalytic and DNA binding activities for these different forms. FL, full-length; NT, N-terminal truncation; CT, C-terminal truncation; NCT, N- and C-terminal truncated. B, Coomassie
staining of purified recombinant Aprataxin and truncated forms (30 pmol of each). FL corresponds to amolecular of 40 kDa; NT, 26 kDa; CT, 37 kDa; NCT, 23 kDa. C, kinetic parameters
for full-length Aprataxin using Ap4A substrate. Activity was determined over the range of substrate concentration (0.02–0.6 mM). Km and Kcat were calculated as described in the
legend to Fig. 6. Velocity is expressed as pmol of AMP produced/pmol of Aprataxin/s. D, kinetic parameters for N-terminal-truncated Aprataxin using Ap4A substrate. Velocity is
expressed as in C above. E, binding of recombinant forms of Aprataxin to DS DNA (2pmol). F, binding of recombinant forms of Aprataxin to SS DNA (2pmol).
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ribose) polymerase 1, XRCC1, p53, and XRCC4 and the increased sen-
sitivity of AOA1 cells to agents that cause single-strand breaks in DNA
(6, 7). It also participates in a novel single-strand break repair complex
together with XRCC1 and DNA ligase 3, and recent evidence shows
that AOA1 cells have a reduced capacity to repair single-strand
breaks in DNA (9, 10). Furthermore, exposure of cells expressing
EGFP-Aprataxin to uranium ions gives rise to EGFP-Aprataxin foci
distributed along particle trajectories as discreet tracts in the nucleus,
demonstrating that it associates with chromatin in response to DNA
damage (6). Complete co-localization with XRCC1 across the length of
these tracts was demonstrated, indicating that both proteins were local-
ized to the same sites of DNA damage. We demonstrated here that a
purified recombinant full-length form of Aprataxin was able to bind
duplex DNA. This was dynamic binding as it was readily competed off
the duplex. The inability of an 8-fold excess of single-strand DNA to
disrupt the Aprataxin double-stranded DNA complex supports a pref-
erence for duplex DNA. The affinity of binding for duplex DNA
increases with increasing duplex length. Reduced affinity of binding was
observed with the 11-bp duplex compared with the 21- and 37-bp frag-
ments. Disruption of the 37-bp duplex with a nick or single nucleotide
gap did not impact on the affinity. The estimated footprint size on
duplex DNA represents approximately one turn of the helix (10 bp).
Aprataxin failed to form a stable complexwith a 21-mer single-strand
oligonucleotide, but formaldehyde cross-linking gave rise to a stable
complex. Increasing the length of the oligonucleotide to a 37-mer
allowed for stable binding without the need for a cross-linker. Under
these conditions only one binding species was observed, whereas 3–4
molecules of Aprataxin bound the 37-bp duplex. The stable binding to
the 37-mer oligonucleotide compared with the 21-mer might be
explained by the capacity to form a secondary structure. Analysis of
secondary structure using OligoAnalyzer 3.0 (Integrated DNA Tech-
nologies) predicts 3 stem loop structures involving 3–7-nucleotide pair-
ing for the 37-mer. Although these predicted structures have low G
values (0.98–1.25 kcalmol1), it is possible that Aprataxin stabilizes the
predicted duplex regions, leading to stable complex formation. None of
these pairings is predicted for the 21-mer. Aprataxin joins a number of
other DNA-binding proteins that display non-sequence-specific DNA
binding characteristics and are involved in DNA repair, transcription,
DNA replication, and chromosome maintenance. In this context a
recent report byWeinberg et al. (21) demonstrated that the C terminus
of p53, expressed in bacteria, binds to nonspecific short double-
stranded DNA fragments as part of a scanning process before finding
specific binding sites. This could well apply to Aprataxin, where it binds
DNA in a nonspecific fashion before finding sites of damage where it
may exert its activity as part of a repair complex.
The DNA binding was not dependent on the deoxyribose portion of
the DNA duplex structure since Aprataxin also bound double-stranded
RNA. This could mean that it has an additional role in the repair or
processing of RNA.We have previously shown that Aprataxin localizes
to both the nucleus and the nucleolus (6). In lymphoblastoid cells, up to
50% of Aprataxin is present in nucleoli, yet the role of Aprataxin in this
subnuclear structure is not yet known. These subnuclear structures are
multifunctional, being the sites for ribosome biogenesis, RNA process-
ing, cell cycle control, and viral replication (22, 23). It is also of interest
that nucleoli have been shown to be a storage site for proteins involved
in DNA damage recognition and repair (23–25). This may also apply to
Aprataxin, but failure to see any net movement of this protein from
nucleoli in response to DNA damage does not support this possibility
(6). Alternatively, it may play an additional role in some aspect of RNA
processing. Its association with an RNA-binding protein, nucleolin in
the nucleolus, supports such a role (6). The double-stranded RNAbind-
ing we observed here may represent the capacity of Aprataxin to bind
secondary structure in mRNA or small nucleolar RNAs as exemplified
by the higher affinity of Aprataxin for the 6-base pair hairpin structures
that would mimic RNA secondary structure.
Three functional domains have been identified in Aprataxin on the
basis of homology (3, 6). These include the FHA domain, which facili-
tates binding to phosphorylated proteins, a HIT domain for nucleotide
binding and hydrolysis, and a putative C-terminal zinc finger that could
allow binding to DNA and or RNA. Although Aprataxin contains only a
single C2H2 type zinc finger domain, the presence of this domain could
be sufficient for DNA binding, but most zinc fingers are usually present
in multiple copies (26). Mendez-Vidal et al. (27) have shown that a
single zinc finger in the mouse Wig1 protein is essential for binding
double-stranded RNA, whereas the two additional zinc fingers are dis-
pensable. Initial DNA binding studies were carried out in the absence of
exogenous zinc, and preincubation with low concentrations of zinc
completely abolished this binding, suggesting that it is unlikely that the
zinc finger motif is responsible for the DNA binding observed here.
Inclusion of EDTA during purification of zinc finger proteins has been
shown to chelate any zinc ions from these proteins (28) and, thus, pre-
vent them from forming the required structure to bind nucleic acid. In
this study purification of recombinant Aprataxin in the presence or
absence of EDTA did not impact on DNA binding, providing further
evidence for lack of dependence on zinc. Interestingly, the HIT domain
mutant, V263G,was unable to bindDNA, suggesting that this domain is
likely to be involved in the DNA binding observed here. But the V263G
protein co-purified with a heat shock protein, indicating the protein
could bemisfolded comparedwith thewild type protein as a result of the
mutation or an artifact of overexpression. The same was found when
this mutant was expressed in a bacterial system (data not shown).
The third functional domain, a centrally located HIT domain, has
been predicted to have nucleotide binding and hydrolase activities (2, 3,
11). We demonstrated here that Aprataxin has hydrolase activity
against HINT and FHITmodel substrates, producing AMP as the prod-
FIGURE 9. Phylogenetic relationships of the HIT superfamily of proteins, with rep-
resentatives from all branches including Aprataxin. The protein sequences from
each branch (indicated by the bracket) including Aprataxin were aligned by ClustalW
then used to build a Neighbor Joining tree (with pairwise deletion) to investigate how
these sequences relate to each other using human CHK2 protein as the root. The boot-
strap test was applied with 1000 replicates, and the values are indicated on the top at
each node. Drerio, Danio rerio; Tnigroviridis, Tetraodon nigroviridis.
Aprataxin Is a Nucleic Acid-binding Protein
13946 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 20•MAY 19, 2006
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
uct of hydrolysis in both reactions, as has been observed for all of the
HINT and FHIT branch proteins investigated to date. A recombinant
form of the HIT domain alone failed to display hydrolase activity.
Aprataxin displayed comparable levels of activity on both the HINT
(AMPNH2) and FHIT (Ap4A) substrates used here. These activities
were 10-fold lower than either of the activities reported for rabbit
Hint1 activity onAMPNH2 (29) and humanFHIT activity onAp4A (30).
The more distinguishing kinetic parameter was Aprataxin affinity,
which was 47-fold higher for the FHIT substrate, Ap4A (Km 18.0M),
than for the HINT substrate, AMPNH2 (Km  837.5 M). An even
better HINT substrate has been identified; this is an AMP linked to a
lysine residue. Rabbit Hint1 displays much higher turnover, Kcat 
0.23s1, and also higher affinity, Km  0.47 M, for this substrate (31).
Seidle et al. (15) recently reported catalytic activity of Aprataxin using
an AMP-lysine-based substrate and found that Aprataxin displayed
100-fold lower affinity (Km 47M) and turnover (Kcat 3 103s1)
than Rabbit Hint1, well belowwhatwould be expected for this branch of
proteins.We observed that removal of the FHAdomain fromAprataxin
did not alter the Km or Kcat for the Ap4A substrate. This contrasts with
two other studies that show either a reduced (15) or increased activity
(13) when the N terminus of the protein is absent. These results might
be explained by the differences in the length of theN-terminal sequence
remaining in the different protein forms.
The presence of DNA duplex and single-stranded DNA to a lesser
extent was able to effectively inhibit the catalytic activity observed here.
This inhibition may be in part due to a conformational change that
occurs in the presence of DNA but may also be due to competition for
the HIT domain. The importance of the HIT domain for the two activ-
ities described here is further supported by disruption of activity by the
V263G mutation in this domain and by retention of activity when the
FHA domain is deleted, but with the remainder of the molecule intact.
Loss of activity by deletion of theC terminus points to the importance of
this end of the molecule in maintaining the proteins catalytic and DNA
binding activities. DNA binding capacity may have evolved through
functional diversification of the HIT domain where the low level of
nucleotide hydrolase activity reported here and by others (13, 15) may
represent residual activity of an ancestral function. Crystallographic
studies in the presence of DNAwill providemore definitive evidence for
theHIT domain inAprataxin representing a novel DNAandRNAbind-
ing domain.
The catalytic activities reported here and elsewhere (13, 15) together
support the notion that none of the substrates assayed, either FHIT or
HINT substrates, display levels of turnover that are likely to be physio-
logically relevant and that Aprataxin may represent a distinct family
within the HIT superfamily, implying that a better substrate is yet to be
identified. The proposal that Aprataxin belongs to or is more closely
related to either the FHIT or HINT branches of the HIT superfamily of
proteins is based on limited sequence and phylogenetic tree analysis (2,
11, 13, 14). The hydrolytic activities determined in this study on nucle-
otide-based substrates and in other studies suggest that Aprataxin has a
unique activity profile distinct from the HINT and FHIT branches (13,
5). We propose that Aprataxin forms a separate branch in the HIT
superfamily of proteins. To further substantiate this, we carried out a
more thorough analysis of the sequence relationships within and
between the HIT superfamily branches using several orthologs from
each branch. Aprataxin was found to form a discrete cluster, like each of
the other previously described branches in the HIT superfamily (HINT,
FHIT, galactose-1-phosphate uridylyltransferase, and DcpS). This clus-
ter like the others is deeply rooted, and the divergence appears to pre-
date the radiation of the eukaryotes, indicating that each family is very
distantly related. This is also supported by the extremely low sequence
identities observed here, for example the pairwise sequence identity of
human Aprataxin and FHIT protein sequences was only 20%. Overall
this suggests that some HIT superfamily members may have evolved by
convergent evolution. This divergent nature of the HIT superfamily
sequences was only recognized when the crystal structure for galactose-
1-phosphate uridylyltransferase protein was compared with Hint1,
allowing it to be classified into theHIT superfamily due to the structural
similarities.
We have described here two functional activities for recombinant
full-lengthAprataxin, which are the capacity to bindRNAandDNAand
the ability to hydrolyze nucleotide based substrates. Several previous
studies using cellular-based investigations including, localization, inter-
actions, and repair assays have implicated Aprataxin in DNA break
repair (6, 9, 10). When combined with the observations made in this
study, demonstrating in vitro binding of Aprataxin to DNA, we propose
that its role may be to scan the genome through its capacity to bind
double-stranded DNA in a sequence-independent manner (Fig. 10). In
response to DNAdamage, Aprataxin would localize to the lesion as part
of a complex with DNA ligase 3 and XRCCI as described by Luo et al.
(9). Once recruited, Aprataxin, through its nucleotide hydrolase activ-
ity, would process the lesion as part of a base excision repairmechanism
(Fig. 10). The increased sensitivity to camptothecin observed in AOA1
cells implicates the topoisomerase 1 cleavage complex as a substrate for
Aprataxin. The more general sensitivity to agents that cause single-
stranded breaks in DNA suggests that Aprataxin may have several such
substrates.
The analysis applied here confirms the classification of the HIT
superfamily with four distinct branches and, in addition, demonstrates
that Aprataxin forms a distinct branch. Furthermore, the data described
here add a new function to theHIT superfamily of proteins, which is the
capacity to bind nucleic acids in addition the ability to bind and hydro-
FIGURE 10.Model of the Aprataxin role in the repair of single-strand breaks. Camp-
tothecin induces the formation of a trapped topoisomerase 1 (TOP1) cleavage complex,
which leads to the recruitment of poly(ADP-ribose) polymerase (PARP) by direct binding
to topoisomerase I as described recently (32). This in turn provides a signal for the
Aprataxin/XRCCI/DNA ligase 3 to locate to the site of damage. This complex has been
reported by Luo et al. (9). It is envisaged that the capacity of Aprataxin to bind duplex
DNA facilitates recruitment of this complex to the site of damage. Formation of this
complex may be enhanced by the known capacity of all of these molecules to interact
(6–9). This would then allow Aprataxin to remove this lesion with its hydrolase activity.
This would be followed by the involvement of the base excision repair machinery.
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lyze nucleotide-based substrates. The challenge ahead is to define the
role of Aprataxin inDNA repair and possibly RNAprocessing and iden-
tify the specific physiological substrates.
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